Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
120 hedge funds and large institutions have $177M invested in Epizyme, Inc in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 56 increasing their positions, 25 reducing their positions, and 33 closing their positions.
1,405% more call options, than puts
Call options by funds: $3.87M | Put options by funds: $257K
124% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 25
9% less funds holding
Funds holding: 132 → 120 (-12)
16% less capital invested
Capital invested by funds: $212M → $177M (-$34.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
36% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RM
RP Management
New York
|
+$37M |
| 2 |
Millennium Management
New York
|
+$6.95M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$6.16M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.64M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$1.85M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$1.73M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.47M |
| 4 |
HF
HRT Financial
New York
|
-$1.42M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.01M |
EPZM Hedge Fund Activity: Q1 2022 in Review
120 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2022, worth a combined $177M — down 16% from $212M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of EPZM and 21 opened new positions — a net loss of 12 holders — while 25 trimmed existing stakes and 56 added.
The largest buyer was RP Management, adding an estimated $37M. The largest seller was Frazier Management, exiting entirely with an estimated $1.85M sold.
- 120 institutional investors held Epizyme, Inc (EPZM) as of Q1 2022, down from 132 in Q4 2021.
- Funds reported $177M of Epizyme, Inc stock for Q1 2022, down 16% quarter-over-quarter.
- 21 funds opened new Epizyme, Inc positions in Q1 2022 and 33 closed out, a net change of -12 holders.
- The largest Epizyme, Inc buyer in Q1 2022 was RP Management, an estimated $37M added.
- The largest Epizyme, Inc seller in Q1 2022 was Frazier Management, an estimated $1.85M sold.
Based on aggregated 13F filings for Q1 2022.